Navigation Links
Prometheus and Bayer HealthCare Enter into Services Agreement to Conduct Mutational Analysis
Date:12/8/2010

SAN DIEGO, Dec. 8, 2010 /PRNewswire/ -- Prometheus Laboratories Inc., a specialty pharmaceutical and diagnostic company, announced today the execution of an oncology-focused mutational analysis services agreement with Bayer Schering Pharma AG, Germany, a worldwide leading pharmaceutical company. The addition of this mutational analysis services agreement broadens Bayer's oncology-focused molecular and pathway activation profiling collaboration with Prometheus to include comprehensive mutational analyses.  The expanded information derived from this agreement has the potential to improve patient stratification in clinical studies and accelerate the development of novel oncology diagnostic and therapeutic products.

Under the terms of this agreement, Bayer will provide clinical samples, sourced from clinical studies, and Prometheus will perform mutational analyses that characterize the presence or absence of existing and novel cancer-relevant mutations in these samples. Prometheus will be compensated based on the number and complexity of mutational analyses it completes for Bayer.

"This agreement represents further validation of the importance of our oncology focused CEER and mutational analysis platforms," said Joseph M. Limber, President and Chief Executive Officer of Prometheus. "The combination of our mutational analysis and CEER platforms that this agreement represents is an important step to providing a more comprehensive analysis to Bayer, that may result in improved selection of patients who will benefit the most from specific drug candidates Bayer is developing. We believe this collaboration has the potential to ultimately result in improved outcomes for patients."

Prometheus and Bayer entered into a research collaboration and license agreement in March of this year. This collaboration partners Prometheus' proprietary oncology diagnostic CEER platform with Bayer's broad oncology pipeline with the objective of stratifying patients to appropriate drug candidates and accelerating the development and market introduction of novel oncology therapeutic and diagnostic products. Using functional pathway analysis, based on Prometheus' CEER platform, promises to enable a comprehensive understanding of tumors leading to improved patient stratification in clinical studies and improved utility and efficacy of targeted cancer therapeutics.

Prometheus' proprietary CEER platform measures the expression and activation of specific cancer pathways with high levels of sensitivity and specificity using tissue or blood samples. The CEER platform has shown great promise to improve the selection and evaluation of the efficacy of drugs in development and in the clinical setting to enable real-time molecular profiling, the monitoring of drug effectiveness in the use of a growing number of targeted therapies.

About Prometheus

Prometheus Laboratories Inc. is committed to improving lives through the development and commercialization of novel pharmaceutical and diagnostic products that enable physicians to provide greater individualized patient care.  Prometheus is a leader in applying the principles of personalized medicine to the diagnosis and treatment of gastrointestinal diseases and is applying these principles to oncology.  Its strategy includes the marketing and delivery of pharmaceutical products complemented by proprietary diagnostic testing services.  By integrating therapeutics and diagnostics, Prometheus believes it can provide physicians with more targeted solutions to optimize care for their patients.  Prometheus' corporate offices are located in San Diego, California.


'/>"/>
SOURCE Prometheus Laboratories Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Prometheus Presents Findings From Development of PROMETHEUS(R) IBS Diagnostic, First Blood Test for IBS, at ACG Annual Scientific Meeting
2. Prometheus and Rosetta Genomics Announce License and Collaboration Agreement
3. Prometheus Announces New Findings Regarding Patients at Risk for Celiac Disease at DDW
4. Prometheus Launches ProOnc Dx Cancer Diagnostics
5. Prometheus Acquires Exclusive Rights to PROLEUKIN(R) (aldesleukin) in the U.S.
6. Prometheus Announces New Method for Real-Time Monitoring of Patients Treated With Biologic Therapy
7. Genzyme and Bayer Schering Pharma AG, Germany Announce Start of Phase 3 Program with Alemtuzumab for Treatment of Multiple Sclerosis
8. Bayer Issues Additional Guidance to Physicians on Trasylol(R)
9. Bayer and Regeneron Dose First Patient in Second Phase 3 Study for VEGF Trap-Eye in Wet Age-Related Macular Degeneration
10. Bayer HealthCare Celebrates 20th Anniversary of Kogenate(R) Product Line and 8 Billion IU Milestone at 2008 WFH World Congress
11. Cell Therapeutics, Inc. (CTI) to Hold Conference Call to Discuss Agreement With Bayer Schering Pharma for Access to Phase III Zevalin(R) FIT Trial Data
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/8/2016)... , Feb. 8, 2016 In a historic vote among ... plans to construct a medical cannabis cultivation facility and dispensary on tribal ... of New York as a provider for patients in the ... York as a provider for patients in the state,s Medical ... 29% (34) to approve the project and pursue designation from the ...
(Date:2/8/2016)... , Feb. 8, 2016 ... the "Knee Reconstruction Devices Market by Product ... Implants), and Geography (U.S., Canada, Eu-5, Japan, Bric, ... 2020" report to their offering. ... of the "Knee Reconstruction Devices Market by ...
(Date:2/8/2016)... , Feb. 8, 2016  The University of ... announced today that, as part of the development ... of the first hospitals in the U.S. to start ... Muraszko , M.D., U-M,s chair of neurosurgery. ... neurosurgery. --> The BrightMatter technology from ...
Breaking Medicine Technology:
(Date:2/8/2016)... ... 08, 2016 , ... Brenton Engineering , powered by ... flow wrapped products at WestPack 2015, February 9-11, in Anaheim, California. This new ... semi-automatic or fully-automatic case packing with a small footprint, rugged, highly flexible, and ...
(Date:2/8/2016)... ... February 08, 2016 , ... Local ... the greater Venice, FL area, has initiated a fundraiser for a two year ... just four days after Christmas. To support this beautiful child who is facing ...
(Date:2/8/2016)... ... February 08, 2016 , ... FileHold's document management software has ... a cloud hosted environment for FileHold software that is pay per user subscription-based ... applications using the FileHold web services API. DocuSyst also advises clients on fully ...
(Date:2/8/2016)... ... February 08, 2016 , ... ... speaking on how healthcare companies can use newly released government data on populations ... a population and intervene and capture the value they create to succeed in ...
(Date:2/7/2016)... Birmingham, Lake Orion, Clarkston, Metamora, Michigan (PRWEB) , ... February 07, ... ... women on Friday in recognition of National Wear Red Day. National Wear Red ... heart disease and stroke in women. Heart disease and stroke cause 1 in 3 ...
Breaking Medicine News(10 mins):